Lilly Q1 revenue up 26% to $8.77B; raises full-year guidance by $2B

ELI LILLY & Co

2024-Q1 EPS reported $2.48 revenue$8,768,000,000

Q1 reported EPS $2.48 (up 66% YoY); non-GAAP EPS $2.58 (up 59% YoY), including $0.10 acquired IPR&D charges.
Revenue $8.77B, driven by Mounjaro, Zepbound, Verzenio, Jardiance; raised FY2024 revenue guidance by $2.0B.
Raises FY2024 reported EPS guidance to $13.05-$13.55 and non-GAAP EPS to $13.50-$14.00.
Pipeline progress: positive Phase 3 tirzepatide for OSA, mirikizumab submission for Crohn's, lebrikizumab resubmission.
Agreement to acquire injectable medicine manufacturing facility from Nexus Pharmaceuticals; broke ground on $2.5B German site.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ELI LILLY & Co reported first quarter of 2024 results: revenue $8,768.0, net income $2,242.9, EPS $2.48. Guidance raised.

Period: first quarter of 2024
Revenue: $8,768.0
Net income: $2,242.9
EPS: $2.48
Guidance: raised
Result: reported results

Exact text from the filing

on important public announcements, visit the news section of Lilly's website. Financial Results $ in millions, except per share data First Quarter 2024 2023 % Change Revenue $ 8,768.0 $ 6,960.0 26% Net income – Reported 2,242.9 1,344.9 67% Earnings per share – Reported 2.48 1.49 66% Net income – Non-GAAP 2,335.3 1,463.9 60% Earnings per share – Non-GAAP 2.58

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-24-000116

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.